Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with 4.25% dextrose is a peritoneal dialysis solution that removes waste products, electrolytes, and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient, drawing fluid and solutes from the capillaries into the peritoneal cavity.
Delflex-LM with Dextrose 2.5% is a peritoneal dialysis solution. Dextrose provides osmotic gradient for ultrafiltration; lactate (LM) is a bicarbonate precursor that buffers metabolic acidosis. The solution replaces fluid and electrolytes while removing waste products via diffusion and convection across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Automated peritoneal dialysis (APD)Management of end-stage renal disease (ESRD)
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, typically 4 exchanges daily (8 liters total). Adjust volume and frequency based on patient's dry weight, residual renal function, and peritoneal membrane transport characteristics.
None Documented
None Documented
Not applicable as a combination solution; glucose half-life ~1.5-2 hours in normal renal function; prolonged in renal impairment.
Dextrose: ~1-2 hours for plasma glucose levels; lactate: ~30-60 minutes for conversion to bicarbonate.
Dextrose is absorbed systemically and metabolized via glycolysis and the Krebs cycle. No hepatic metabolism for the solution components; waste removal is achieved through peritoneal dialysis. Insulin may be required to manage hyperglycemia.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; lactate is converted to bicarbonate in the liver and kidneys via lactate dehydrogenase.
Renal: >90% as unchanged glucose and electrolytes; negligible biliary/fecal elimination.
Peritoneal dialysis fluid components: dextrose is metabolized to CO2 and water; lactate is converted to bicarbonate in liver; electrolytes are variably reabsorbed. ~70% of administered dextrose is absorbed; elimination primarily via metabolic pathways.
Minimal (<10%); glucose and electrolytes do not significantly bind to plasma proteins.
Dextrose: negligible; lactate: <10% bound to albumin.
Glucose: ~0.2 L/kg (extracellular fluid); electrolytes distribute according to body water compartments.
Dextrose: Vd ~0.25 L/kg (total body water); lactate: Vd ~0.5 L/kg.
Intraperitoneal: ~70-80% for glucose absorption; electrolytes 100% bioavailable via peritoneal route.
Not applicable: intraperitoneal administration bypasses gastrointestinal absorption; dextrose absorption ~70-80% of administered dose over dwell time.
Not applicable; drug is used for renal replacement therapy in end-stage renal disease.
Dosing is titrated based on residual renal function and peritoneal dialysis adequacy. For patients with GFR <10 mL/min, standard regimen is used. Adjust exchange volume and number to achieve weekly Kt/V ≥1.7.
No specific adjustments; monitor for metabolic acidosis and electrolyte imbalances in severe hepatic impairment.
No specific Child-Pugh based dose adjustments; monitor for glucose intolerance and fluid overload. In severe hepatic impairment, consider reduced dextrose concentration to avoid hyperglycemia.
Weight-based: 30 to 40 mL/kg per exchange, 4 to 5 exchanges per day; adjust based on residual renal function and ultrafiltration needs.
Initial exchange volume: 10-20 mL/kg per exchange, up to 1100 mL/m² body surface area per exchange. Number of exchanges: 4-5 per day. Titrate based on ultrafiltration and metabolic control.
No specific dose adjustments; monitor glucose and electrolyte levels closely due to higher risk of hyperglycemia and fluid overload.
Start with lower exchange volumes (1.5-2 liters) and monitor for fluid overload and electrolyte imbalances. Adjust dextrose concentration to minimize hyperglycemia. Use same exchange frequency as adults.
Peritoneal dialysis solutions with dextrose, including Delflex with 4.25% dextrose, are contraindicated in patients with pre-existing severe hyperglycemia or who are hypersensitive to any component of the product. The solution is for peritoneal administration only, not for intravenous use. Strict sterile technique in catheter placement and fluid exchange is required to prevent peritonitis.
None
["Hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus","Peritonitis and exit-site infections; strict aseptic technique required","Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) due to low magnesium and low calcium formulation","Protein loss and malnutrition","Fluid overload or dehydration (monitor fluid balance)","Hernias and abdominal discomfort","Peritoneal catheter complications"]
Peritonitis risk; monitor for hyperglycemia, volume overload, hypokalemia, hypomagnesemia, and acidosis; strict aseptic technique; not for IV use; monitor serum electrolytes and glucose.
["Hypersensitivity to any component","Pre-existing severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions, fibrosis, or sclerosis","Abdominal wall infection or peritonitis","Recent abdominal surgery or trauma","Severe pulmonary disease (risk of respiratory compromise)","Collagen vascular disease (e.g., scleroderma)","Uncorrectable mechanical defects (e.g., catheter malfunction)"]
Pre-existing severe lactic acidosis, hypersensitivity to any component, documented inability to perform peritoneal dialysis, recent abdominal surgery with prosthetic material, severe abdominal wall infection or burn, pregnancy (relative).
Data Pending Review
Data Pending Review
No direct food interactions, but patients on peritoneal dialysis may require dietary restrictions for potassium, phosphorus, and sodium. Avoid excessive intake of calcium- or magnesium-rich foods (e.g., dairy, nuts, leafy greens) if monitoring indicates imbalances. Dextrose absorption may affect blood glucose; manage carbohydrate intake accordingly.
No direct dietary interactions with the dialysis solution itself. However, patients on peritoneal dialysis should follow a renal diet: limit sodium, potassium, phosphorus, and fluid intake as advised. Avoid high-phosphorus foods (dairy, nuts, colas) and high-potassium foods (bananas, oranges, potatoes). Use salt substitutes only if recommended, as they may contain potassium. Maintain adequate protein intake unless restricted. Consult a renal dietitian for individualized meal planning.
Delflex w/ Dextrose 4.25% Low Magnesium Low Calcium is a peritoneal dialysis solution. There are no adequate studies in pregnant women. Peritoneal dialysis itself may pose risks (e.g., infection, preterm labor). Dextrose may cause maternal hyperglycemia and fetal hyperinsulinism. Use only if clearly needed, weighing risks vs benefits. Trimester-specific risks are not established; reports of congenital anomalies are not directly attributed to the solution.
Peritoneal dialysis solutions are generally considered low risk due to minimal systemic absorption. No specific teratogenic effects reported; however, electrolyte imbalances or metabolic disturbances from improper use could theoretically affect fetal development. Use only if clearly indicated.
It is unknown whether Delflex components are excreted in human milk. Dextrose and electrolytes are endogenous substances. The M/P ratio is not available. Caution is advised; consider risk of infant exposure to small amounts of dialysate components.
No data on excretion into breast milk. Clinically insignificant systemic absorption suggests minimal risk to nursing infant. Caution with additives (e.g., dextrose, electrolytes). M/P ratio not available.
No specific dose adjustment recommendations during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered electrolyte needs) may require careful monitoring and adjustment of exchange volume, frequency, and electrolyte composition to maintain metabolic control. Consult nephrology for individualized therapy.
No standard dose adjustments required due to minimal systemic absorption. However, increased maternal plasma volume and altered electrolyte needs may necessitate adjustment of dialysis prescription (e.g., dextrose concentration, volume) to avoid hypoglycemia, hyperglycemia, or electrolyte disturbances. Individualize based on maternal and fetal status.
Category C
Category C
This solution is used in peritoneal dialysis. The low magnesium and low calcium formulation is indicated for patients with hypermagnesemia or hypercalcemia, or to adjust electrolyte balance. Monitor serum magnesium and calcium levels regularly. The 4.25% dextrose concentration provides higher ultrafiltration; use with caution in patients with hyperglycemia or insulin-dependent diabetes. Check for solution cloudiness or leaks before use. Warm solution to body temperature before infusion to reduce discomfort.
DELFLEX-LM W/ DEXTROSE 2.5% is a peritoneal dialysis solution with low magnesium (0.5 mEq/L) and low calcium (2.5 mEq/L), suitable for patients with hypercalcemia or to reduce calcium load. Monitor serum electrolytes, especially potassium and magnesium, during therapy. Do not use if solution is discolored or contains particulate matter. Warm solution to body temperature before use to reduce discomfort. Use aseptic technique to prevent peritonitis. Verify correct dextrose concentration to avoid unintended hyperglycemia.
Follow strict sterile technique during bag exchange to prevent peritonitis.Check the solution for clarity, color, and leaks before use.Warm the solution to body temperature before infusion for comfort.Monitor for signs of infection (abdominal pain, fever, cloudy effluent) and report immediately.Keep a log of your weight, blood pressure, and inflow/outflow volumes.Do not modify the solution composition without consulting your healthcare provider.
Inspect the bag for any leaks or cloudy solution before use; do not use if damaged or discolored.Warm the solution to body temperature (approximately 37°C) by placing the bag in a warm water bath—do not microwave.Wash hands thoroughly and use sterile technique when connecting and disconnecting the dialysis lines.Report any signs of infection such as fever, abdominal pain, or cloudy drainage fluid immediately.Monitor blood glucose regularly as the dextrose in the solution can raise blood sugar.Adhere to the prescribed dialysis schedule and do not skip or extend exchanges without medical advice.